CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Author's Avatar
Jun 20, 2023
  • Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma
  • Study designed to evaluate safety and immunogenicity in patients with glioblastoma after surgical resection and radiotherapy
  • First study to apply CureVac's second-generation mRNA backbone in oncology